Plasma Level of Placenta-Derived Macrophage-Stimulating Protein -Chain in Preeclampsia before 20 Weeks of Pregnancy

• Published in: PloS one 2016-08, Vol.11 (8), p.e0161626-e0161626
• Main Authors: Zhang, Yonggang, Yang, Hongling, Long, Yan, Ma, Qingling, Chen, Ruihua
• Format: Article
• Language: English
• Subjects: Adult; Age; Analysis; Area Under Curve; Authorship; Biology and Life Sciences; Biomarkers; Body mass; Body Mass Index; Case-Control Studies; Chains; Complications and side effects; Diagnosis; Diagnostic systems; Embryos; Female; Genetic aspects; Gestation; Gestational Age; Health care; Hepatocyte Growth Factor - blood; Humans; Hypertension; Laboratories; Ligands; Macrophage-stimulating protein; Macrophages; Macrophages - metabolism; Maternal Age; Medicine and Health Sciences; Optical density; Pathogenesis; Physiological aspects; Placenta; Placenta - metabolism; Plasma; Pneumoviridae; Pre-eclampsia; Pre-Eclampsia - blood; Preeclampsia; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Proteins; Proto-Oncogene Proteins - blood; Research and Analysis Methods; Staining; Surveys and Questionnaires; Vascular endothelial growth factor; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0161626

This study aimed to investigate the diagnostic value of placenta-derived macrophage-stimulating protein α-chain (MSP-α) before the 20th week of gestation for the early diagnosis of preeclampsia (PE). Two parts of this nested case-control study were simultaneously executed, and 1500 pregnant women were recruited. A total of 124 pregnant women were included in the plasma analysis part of this study. The MSP-α plasma level was measured before the 20th week of gestation, and the participants were followed until delivery. A case group of 62 women with PE and a control group of 62 women matched by gestational age, maternal age, and pre-pregnancy BMI (with normotensive pregnancies) were evaluated. In the placenta analysis part of this nested case-control study, the placentas of 34 pregnant women were randomly obtained. The placental levels of MSP were measured in 17 individuals with PE (case group) and in 17 women with a normotensive pregnancy matched by gestational age and maternal age (control group). The plasma level of MSP-α was higher in the PE group than in the control group before the 20th week of gestation (p < 0.001). In addition, compared to the women with severe features in the PE group, those without severe features had a significantly higher plasma MSP-α level before the 20th week of gestation (p < 0.001). The area under the receiver operating characteristic curve (AUC) of MSP-α before the 20th week of gestation was 0.905 (95% CI, 0.811-0.962) for the women with early-onset PE without severe features. With regard to the placenta, the PE group (accumulated optical density, IOD [SUM] = 8862.37 ± 2064.42) exhibited increased MSP staining (more intense MSP staining or more extensive staining) compared with the control group (normal pregnancies (IOD [SUM] = 447.92 ± 114.72, P < 0.001). Furthermore, increased MSP staining was detected among the women without severe features compared with those with severe features in the PE group (IOD [SUM]: 12192.65 ± 5325.56 vs. 4104.83 ± 2383.06, P = 0.021). According to the findings of this study, the plasma level of MSP-α may be associated with PE, and MSP-α may be considered a candidate protein for further analysis in studies of PE. Multicenter studies with larger sample sizes must be performed in the future to obtain accurate results regarding the predictive value of MSP-α in combination with other protein factors for the early diagnosis of PE.